Is Immunovant, Inc. profitable?

Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.

What is Immunovant, Inc.'s earnings per share?

Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.

Where does Immunovant, Inc.'s income statement data come from?

Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Immunovant, Inc. IMVT Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q4 '26	Q3 '26	Q2 '26	Q1 '26	Q4 '25
Research and development	$142.29M+43.8%	$98.92M-13.4%	$114.25M+12.9%	$101.2M+8.1%	$93.65M-0.9%
General and administrative	$17.27M+11.8%	$15.44M-11.8%	$17.51M-32.7%	$26.02M+29.0%	$20.17M+2.0%
Other operating expenses	$159.55M+39.5%	$114.36M-13.2%	$131.76M+3.6%	$127.22M+11.8%	$113.83M-0.4%
Total operating expenses	$159.55M+39.5%	$114.36M-13.2%	$131.76M+3.6%	$127.22M+11.8%	$113.83M-0.4%
Interest expense	$8.06M+51.1%	$5.33M-4.8%	$5.6M-11.6%	$6.34M-8.0%	$6.89M+50.1%
Other income (expense), net	$798K+1,578%	-$54K-122%	$250K-78.9%	$1.19M+10.8%	$1.07M+185%
Income before income taxes	-$150.7M-38.2%	-$109.08M+13.4%	-$125.91M-5.2%	-$119.7M-13.1%	-$105.87M+4.6%
Income tax expense	——	$1.55M+161%	$594K-34.9%	$913K+56.6%	$583K+284%
Net income	-$147.86M-33.6%	-$110.64M+12.5%	-$126.5M-4.9%	-$120.61M-13.3%	-$106.45M+4.2%
Diluted earnings per share	-$0.73-19.7%	-$0.61+16.4%	-$0.73-2.8%	-$0.71-12.7%	-$0.63+17.1%
Basic earnings per share	-$0.73-19.7%	-$0.61+16.4%	-$0.73-2.8%	-$0.71-12.7%	-$0.63+17.1%
Weighted-average shares, diluted	182.4M+0.5%	181.5M+4.5%	173.6M+1.6%	170.9M+12.7%	151.6M+3.2%
Weighted-average shares, basic	182.4M+0.5%	181.5M+4.5%	173.6M+1.6%	170.9M+12.7%	151.6M+3.2%
Interest Income (Expense), Nonoperating	$8.06M+51.1%	$5.33M-4.8%	$5.6M-11.6%	$6.34M-8.0%	$6.89M+50.1%
Other income, net (Note 6)	$798K+1,578%	-$54K-122%	$250K-78.9%	$1.19M+10.8%	$1.07M+185%
Research and development expense	$142.29M+43.8%	$98.92M-13.4%	$114.25M+12.9%	$101.2M+8.1%	$93.65M-0.9%
EBITDA	-$142.55M-37.5%	-$103.65M+13.8%	-$120.2M-6.1%	-$113.26M-14.6%	-$98.87M+7.0%
EBIT	-$142.64M-37.5%	-$103.75M+13.8%	-$120.3M-6.1%	-$113.36M-14.5%	-$98.98M+7.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Is Immunovant, Inc. profitable?: Immunovant, Inc. is not currently profitable: it reported a net loss of $505.6M over the trailing twelve months.
What is Immunovant, Inc.'s earnings per share?: Immunovant, Inc.'s diluted EPS over the trailing twelve months is $-2.78.
Where does Immunovant, Inc.'s income statement data come from?: Every line is extracted from Immunovant, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.